Artiva Biotherapeutics, Inc. Increase (Decrease) in Other Receivables
Artiva Biotherapeutics, Inc. (ARTV) reported Increase (Decrease) in Other Receivables of $74.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2026-06-30 was $141.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2026-03-31 was -$67.00K, a 176.14% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2025-12-31 was -$12.00K, a 185.71% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for the quarter ending 2025-09-30 was $49.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for fiscal 2025 was -$79.00K.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for fiscal 2024 was -$578.00K, a 179.83% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. increase (decrease) in other receivables for fiscal 2023 was $724.00K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $74.00K 10-Q · filed 2026-08-06 | $62.00K derived: sum of 3 quarters · filed 2026-08-06 | $111.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$67.00K 10-Q · filed 2026-05-08 | -$79.00K derived: sum of 2 quarters · filed 2026-05-08 | -$30.00K derived: sum of 3 quarters · filed 2026-05-08 | -$234.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $37.00K derived: sum of 2 quarters · filed 2026-03-10 | -$167.00K derived: sum of 3 quarters · filed 2026-08-06 | -$79.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$155.00K derived: sum of 2 quarters · filed 2026-08-06 | -$67.00K 10-Q · filed 2025-11-12 | -$53.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$116.00K 10-Q · filed 2026-08-06 | -$102.00K derived: sum of 3 quarters · filed 2026-08-06 | -$862.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $88.00K 10-Q · filed 2026-05-08 | $102.00K derived: sum of 2 quarters · filed 2026-05-08 | -$658.00K derived: sum of 3 quarters · filed 2026-05-08 | -$670.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$746.00K derived: sum of 2 quarters · filed 2026-03-10 | -$758.00K derived: sum of 3 quarters · filed 2026-03-10 | -$578.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | -$760.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$772.00K derived: sum of 2 quarters · filed 2025-11-12 | -$592.00K 10-Q · filed 2025-11-12 | -$1.21M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $168.00K 10-Q · filed 2025-08-06 | -$446.00K derived: sum of 3 quarters · filed 2025-08-06 | $213.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $180.00K 10-Q · filed 2025-05-08 | -$434.00K derived: sum of 2 quarters · filed 2025-05-08 | $225.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$614.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $45.00K derived: sum of 2 quarters · filed 2025-03-24 | $724.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $659.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.34M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $679.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |